Brief: HLS Therapeutics Q2 Loss Per Share $0.06

HLS Therapeutics

08/08/2019 11:41

Aug 8 (Reuters) - HLS Therapeutics Inc  HLS.TO :
    * HLS THERAPEUTICS ANNOUNCES Q2 2019 FINANCIAL RESULTS
    * QTRLY REVENUE OF $13.6 MILLION
    * Q2 LOSS PER SHARE $0.06
    * TIMING OF CLOZARIL ORDERS ORDERS IMPACTED Q2 REVENUE BUT
SHOULD
HAVE A FAVORABLE IMPACT IN Q3
    * AS AT JUNE 30, 2019, COMPANY HAD CASH AND CASH EQUIVALENTS
OF
$52.3 MILLION, UP FROM $10.9 MILLION AT DECEMBER 31, 2018

Source text for Eikon:  ID:nCNW5wyn9a 
Further company coverage:  HLS.TO 

 ((Reuters.Briefs@thomsonreuters.com;))